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Introduction
Eclampsia is a serious complication of pregnancy that
substantially contributes to maternal mortality and
morbidity [1]. Eclamptic patients usually require inten-
sive care during the pre- and postpartum period.
Additionally, they have a longer hospitalization time
than healthy pregnant women.
Factors influencing the length of hospital stay in
eclamptic patients have received less attention in the
literature. Determining the factors influencing the hos-
pitalization period may help decrease the length of
hospital stay, reduce costs, and improve efficiency in
perinatology units.
The aim of this study was to determine the variables
associated with postpartum length of hospital stay in
eclamptic patients.
Materials and Methods
In this retrospective study, the sample consisted of 
98 eclamptic patients who were admitted to our 
perinatology unit between January 1998 and May
2003.
The definition of eclampsia was in accordance with
the criteria of Cunningham et al [2]. Age, gravida, par-
ity, and gestational age were the patient characteris-
tics noted. Hematologic and biochemical parameters
measured at the time of admission were provided from
hospital records.
All patients received magnesium sulfate seizure pro-
phylaxis during the intrapartum period, which consisted
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of a 4.5g loading dose and a 2.0g per hour maintenance
dose. Vital signs were assessed every hour until the time
of hospital discharge.
Data obtained from the patients’ obstetric records
included delivery route, maternal complications, prepar-
tum follow-up period, and the length of postpartum
hospitalization stay.
The study sample was divided into two groups
according to the postpartum length of stay: the short-
stay group (1–3 days) consisted of 33 patients and 
the long-stay group (4 days and longer) consisted of 
65 patients.
The groups were compared with respect to the
demographic characteristics, laboratory and clinical
parameters, use of magnesium therapy, and other med-
ical complications.
All data were analyzed using SPSS software (SPSS
Inc, Chicago, IL, USA). For statistical analysis, the two-
tailed Student’s t test, Mann–Whitney U test, and
Fisher’s exact test were used. Statistical significance
was considered to be reached at p < 0.05.
Results
The mean age of the patients was 23.59 ± 5.67 years in
the short-stay group and 24.03 ± 5.57 years in the
long-stay group. Sociodemographic characteristics of
the patients are presented in Table 1. There were no
significant differences between the two groups in
terms of age, gravida, parity, and gestational age
(p > 0.05) (Table 1). One patient (3.03%) in the short-
stay group and ten patients (15.38%) in the long-stay
group had a history of antihypertensive treatment dur-
ing antepartum period (p = 0.049).
The hematologic and biochemical parameters
measured at the time of admittance are presented in
Table 2. Both groups were similar in hematologic and
biochemical parameters, with the exception of serum
fibrinogen, urea, and alanine and aspartate aminotrans-
ferase levels (p > 0.05). The short-stay group had lower
serum fibrinogen and urea levels and higher serum ala-
nine and aspartate aminotransferase levels than the
long-stay group (p < 0.05) (Table 2).
Table 1. Sociodemographic characteristics of patients*
Short-stay group (n = 33) Long-stay group (n = 65) p
Maternal age (yr) 23.59 ± 5.67 24.03 ± 5.57 0.599
Gravida 2.03 ± 1.51 2.44 ± 4.68 0.516
Parity 0.67 ± 0.85 0.69 ± 1.18 0.903
Nulliparous 18/33 (54.54) 42/65 (64.61) 0.336
Primigravidas 17/33 (51.51) 37/65 (56.92) 0.613
Gestational age (wk) 33.76 ± 4.73 32.89 ± 4.19 0.435
History of antihypertensive treatment 1/33 (3.03) 10/65 (15.38) 0.049†
Chronic hypertension 1/33 (3.0) 4/65 (6.2) 0.507
*Data are presented as mean ± standard deviation or n (%); †statistically significant.
Table 2. The hematologic and biochemical parameters measured at the time of admittance*
Short-stay group (n = 33) Long-stay group (n = 65) p
Hemoglobin (g/dL) 12.13 ± 1.72 12.09 ± 1.65 0.060
Hematocrit (%) 36.53 ± 5.63 38.39 ± 4.76 0.110
Platelet cell count (per mm3) 221,655 ± 117,437 193,846 ± 89,076 0.237
Platelets < 100,000 7/33 (21.20) 13/65 (20.0) 0.888
Prothrombin time (sec) 12.93 ± 2.59 17.64 ± 42.40 0.375
Activated partial thromboplastin time (sec) 29.26 ± 5.01 29.25 ± 5.05 0.996
Fibrinogen (mg/dL) 445.12 ± 177.49 472.43 ± 152.49 0.048†
Serum urea (mg/dL) 30.33 ± 16.07 34.49 ± 14.86 0.050†
Serum creatinine (mg/dL) 0.87 ± 0.49 0.93 ± 0.42 0.569
ALT (U/L) 150.54 ± 339.21 73.13 ± 110.85 0.035†
AST (U/L) 226.60 ± 349.20 112.64 ± 192.29 0.040†
Total protein (g/dL) 6.4 ± 1.18 6.03 ± 1.08 0.219
Albumin (g/dL) 3.10 ± 0.49 3.00 ± 0.71 0.572
Proteinuria ≥ 300 mg/dL 20/33 (60.6) 50/65 (76.9) 0.260
Urea/creatinine 36.38 ± 12.71 38.56 ± 12.71 0.426
*Data are presented as mean ± standard deviation or n (%); †statistically significant. ALT = alanine aminotransferase; AST = aspartate aminotransferase.
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The comparison of the clinical parameters between
the groups is shown in Table 3. The proportion of
patients receiving magnesium sulfate therapy longer
than 12 hours was higher in the long-stay group
(p = 0.014). Likewise, the long-stay group had higher
diastolic arterial blood pressure than the short-stay
group (p = 0.006).
The total cesarean delivery rate for the short-stay
group was 48.5%, compared with 67.7% in the long-stay
group (p = 0.081). The mean length of hospital stay 
in eclamptic patients was 4.5 ± 2.3 days (range, 1–14
days). The mean hospitalization periods for the short-
stay and long-stay groups were 2.48 ± 0.79 and 5.60 ±
2.12 days, respectively. When the groups were com-
pared in terms of the prepartum follow-up period (the
interval between onset of eclampsia and delivery), it
was longer in the long-stay group than in the short-stay
group (12.11 ± 27.63 vs. 5.08 ± 6.08 hours) (p = 0.060)
(Table 3). Maternal complications were similar in both
groups (p = 0.572).
Discussion
Eclampsia continues to be a poorly understood neuro-
logic complication of pregnancy that substantially
contributes to maternal morbidity and mortality.
Maternal mortality rates range from 0.5% to 14% [3].
Delivery is the only definitive treatment of eclampsia.
The current recommendation is immediate delivery
when the convulsions are controlled and the woman’s
condition is stabilized regardless of gestational age
[4]. In our study, the prepartum follow-up period was
shorter in the short-stay group than in the long-stay
group. Early delivery, the main treatment of eclampsia,
may provide prompt clinical recovery that leads to a
shorter hospital stay.
Although no randomized clinical trials have evaluated
the optimal method of delivery for women with eclamp-
sia, several investigators concluded that the method of
delivery in eclamptic patients should depend on fac-
tors such as gestational age, fetal presentation, and
findings of the cervical examination [1]. The rate of
cesarean delivery in eclamptic patients ranges between
11% and 57% [5]. Cunningham and Gant reported that
serious maternal morbidity was less common during the
puerperium in women with vaginal delivery [6]. In our
study, the rate of cesarean delivery was higher in the long-
stay group than in the short-stay group, even though it
did not reach statistical significance. Higher cesarean
section rate leads to a longer hospital stay by delaying
clinical recovery in eclampsia and prolonging the need of
hospitalization because of surgery-related morbidity.
As morbidity and mortality in eclampsia are related
to the number of convulsions, convulsion control is very
important in its management. Many trials have been
conducted to determine the efficacy of drugs in prevent-
ing and controlling eclamptic seizures. The Eclampsia
Trial Collaborative Group proved the superiority of mag-
nesium sulfate for reducing recurrence of seizures [7].
However, there is no agreement in the published ran-
domized trials regarding the dose to use, the route of
administration, as well as the duration of therapy.
Although magnesium sulfate therapy is often arbitrarily
given for 12–24 hours after delivery, depending on
severity of disease, there are reports suggesting that an
individualized clinically based regimen is apparently an
alternative option [8–10]. Some investigators believe
Table 3. The comparison of the clinical parameters between the groups*
Short-stay group (n = 33) Long-stay group (n = 65) p
Systolic blood pressure (mmHg)† 154.24 ± 27.50 159.38 ± 22.83 0.359
Diastolic blood pressure (mmHg)† 97.87 ± 17.09 108.15 ± 17.03 0.006‡
Duration of MgSO4 treatment (hr) 18.68 ± 7.38 23.03 ± 6.81 0.006‡
MgSO4 treatment ≥ 12 hours 22/33 (67.7) 58/65 (89.2) 0.014‡
Prepartum follow up period (hr) 5.08 ± 6.08 12.11 ± 27.63 0.060
Labor induction 12/33 (36.36) 25/65 (38.46) 0.510
Cesarean delivery 16/33 (48.5) 44/65 (67.7) 0.081
Postpartum eclampsia 5/33 (15.1) 4/65 (6.1) 0.147
HELLP syndrome 8/33 (24.2) 25/65 (38.5) 0.153
Hospitalization period (days) 2.48 ± 0.79 5.6 ± 2.12 0.010‡
Maternal complications (pulmonary, renal 2/33 (6.06) 5/65 (7.69) 0.572
cardiovascular, neurologic complications)
*Data are presented as mean ± standard deviation or n (%); †value is the average measured on two occasions at least 6 hours apart; ‡statistically significant.
HELLP = hemolysis, elevated liver enzymes and low platelet count.
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that higher dose or longer duration is unlikely to confer
greater benefit but would almost certainly be associated
with more side effects and a greater risk of toxicity [11].
In a recent study, the authors reported that a 12-hour
maintenance therapy is as effective as the traditional
24-hour regimen [12]. In our study, the duration of
magnesium therapy was significantly shorter in the
short-stay group. Higher diastolic pressure in the long-
stay group might be responsible for the longer magne-
sium therapy.
In a study of 446 eclamptic patients, the authors
concluded that mortality by eclampsia is directly related
to age, diastolic hypertension, seizure, and thrombo-
cytopenia [13]. In our study, as a reflection of severity
of disease, patients in the long-stay group had a higher
diastolic blood pressure than those in the short-stay
group.
Women who develop eclampsia are at increased risk
for a number of complications. A syndrome of hemoly-
sis, elevated liver enzymes, and a low platelet count,
known as the HELLP syndrome, can complicate up to
10% of eclamptic cases [14,15]. Mortality resulting
from the HELLP syndrome ranges from 2% to 24% of
cases. In this study, although the level of liver enzymes on
admittance was higher in the short-stay group, HELLP
syndrome developed more often during the follow-up
in the long-stay group. This was probably because of the
longer interval between onset of eclampsia and deliv-
ery and the higher diastolic blood pressure in the long-
stay group.
This study has some limitations. Firstly, the study
population was not large enough to draw an accurate
conclusion. Secondly, as the study design was retrospec-
tive, other parameters such as social and economic fac-
tors that might affect the length of hospital stay could
not be evaluated. Thirdly, we were unable to obtain a
definitive normalization time of liver enzymes after
delivery, because the intervals that blood samples were
obtained varied between patients. We were also unable
to determine the time taken for diastolic pressure to
return to normal after delivery, because some of the
patients were still hypertensive at the time of discharge.
To our knowledge, this is the first report on factors
influencing the length of hospital stay in eclamptic
patients. In our opinion, further prospective investiga-
tions involving large number of cases are needed to
confirm these findings.
In conclusion, our findings suggest that the length of
hospital stay in eclamptic patients is mainly affected
by the diastolic blood pressure, the interval between
onset of eclampsia and delivery, mode of delivery, and
duration of magnesium therapy. However, prognostic
advantages of these subjects have yet to be defined;
therefore, management of eclamptic patients should
be individualized.
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